Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Carly A. Conran"'
Autor:
Carly A. Conran, Zhuqing Shi, William Kyle Resurreccion, Rong Na, Brian T. Helfand, Elena Genova, Siqun Lilly Zheng, Charles B. Brendler, Jianfeng Xu
Publikováno v:
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-9 (2021)
Abstract Background Genome-wide association studies have identified thousands of disease-associated single nucleotide polymorphisms (SNPs). A subset of these SNPs may be additively combined to generate genetic risk scores (GRSs) that confer risk for
Externí odkaz:
https://doaj.org/article/584e3d541e5b4f18b416ceca3f3ae1b6
Autor:
Carly A Conran, Rong Na, Haitao Chen, Deke Jiang, Xiaoling Lin, S Lilly Zheng, Charles B Brendler, Jianfeng Xu
Publikováno v:
Asian Journal of Andrology, Vol 18, Iss 4, Pp 520-524 (2016)
Several different approaches are available to clinicians for determining prostate cancer (PCa) risk. The clinical validity of various PCa risk assessment methods utilizing single nucleotide polymorphisms (SNPs) has been established; however, these SN
Externí odkaz:
https://doaj.org/article/0d78f7d9cc264e1aafd2ed12f84275ca
Publikováno v:
Asian Journal of Andrology, Vol 18, Iss 4, Pp 505-508 (2016)
Unprecedented progress has been made in genomic personalized medicine in the last several years, allowing for more individualized healthcare assessments and recommendations than ever before. However, most of this progress in prostate cancer (PCa) car
Externí odkaz:
https://doaj.org/article/bc868349af2446cd905532ab57f00c47
Autor:
Carly A, Conran, Larry W, Moreland
Publikováno v:
Current Opinion in Pharmacology. 64:102234
Biologics are effective, though costly, medications for the treatment of rheumatoid arthritis (RA). Biosimilars are medications that have no clinically meaningful differences when compared with their corresponding reference biologics but cost signifi